During the past decade, Phoenix Neurological Associates, Ltd. conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 15 clinical trials were completed, i.e. on average, 115.4% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 9 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Phoenix Neurological Associates, Ltd." #1 sponsor was "Phoenix Neurological Associates, LTD" with 5 trials, followed by "Genentech, Inc." with 4 trials sponsored, "Biogen" with 3 trials sponsored, "University of Kansas Medical Center" with 3 trials sponsored and "Hoffmann-La Roche" with 3 trials sponsored. Other sponsors include 12 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Phoenix Neurological Associates, Ltd." #1 collaborator was "ALS Association" with 2 trials as a collaborator, "National Institute of Neurological Disorders and Stroke (NINDS)" with 2 trials as a collaborator, "University College, London" with 2 trials as a collaborator, "University of Kansas Medical Center" with 2 trials as a collaborator and "ALS Therapy Alliance" with 1 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "Phoenix Neurological Associates, Ltd." are "Amyotrophic Lateral Sclerosis" (9 trials), "Multiple Sclerosis" (6 trials), "Inclusion Body Myositis" (3 trials), "Multiple Sclerosis, Relapsing-Remitting" (3 trials) and "Myasthenia Gravis" (3 trials). Many other conditions were trialed in "Phoenix Neurological Associates, Ltd." in a lesser frequency.

Most popular intervention types in "Phoenix Neurological Associates, Ltd." are "Drug" (31 trials), "Other" (7 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Ocrelizumab" (5 trials), "Arimoclomol" (2 trials), "Avonex" (2 trials) and "Memantine" (2 trials). Other intervention names were less common.

The vast majority of trials in "Phoenix Neurological Associates, Ltd." are 34 trials for "All" genders.

Currently, there are NaN active trials in "Phoenix Neurological Associates, Ltd.". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 29 completed trials in Phoenix Neurological Associates, Ltd., undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Phoenix Neurological Associates, Ltd., 3 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".